Education
About Us
Working with TipRanks
Follow Us
D.Western Therapeutics Institute, Inc. (JP:4576)
:4576
4576 Stock Chart & Stats
¥105.00
-¥3.00(-1.74%)
At close: 4:00 PM EST
¥105.00
-¥3.00(-1.74%)
Day’s Range― - ―
52-Week Range¥87.00 - ¥181.00
Previous CloseN/A
Volume3.18M
Average Volume (3M)623.89K
Market Cap
¥5.38B
Enterprise Value¥3.28B
Total Cash (Recent Filing)¥1.05B
Total Debt (Recent Filing)¥517.95M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding54,356,712
10 Day Avg. Volume615,690
30 Day Avg. Volume623,886
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high gross margins (~78% in 2025, historically ~90%+) indicate attractive unit economics for the company’s products/platform. Over the medium term, strong gross margins provide structural leverage to scale revenue into higher operating profitability once R&D and SG&A stabilize.
Improving LeverageDebt-to-equity falling to ~0.42 in 2025 from ~1.09 in 2024 shows materially improved leverage and a stronger equity base. This durable capital-structure improvement reduces refinancing and solvency risk, supporting runway for development programs and potential strategic partnerships.
Reduced Cash Burn TrendOperating burn improving materially year-over-year signals better cost control and cash conservation. A persistent downward trend in burn extends financing runway, increases the chance of reaching development milestones without immediate dilutive raises, and strengthens negotiating leverage with partners.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow are negative every year shown, so the company must rely on external financing to operate. This persistent cash burn is a lasting constraint that raises dilution and financing-cost risk, limiting strategic flexibility until cash flow turns positive.
Small, Volatile RevenueSmall, volatile revenue reflects development-stage commercial traction and raises predictability issues. Structurally low and fluctuating top-line limits internal funding capacity, complicates scaling fixed costs, and makes multi-month planning and milestone funding dependent on external capital or partnerships.
Deep, Persistent LossesNet losses exceeding revenue (net margin ~-163% in 2025) and historically negative returns on equity indicate the business is not self-funding. Sustained unprofitability is a structural headwind that requires clinical, regulatory, or commercial breakthroughs to reverse before internal capital generation becomes viable.
D.Western Therapeutics Institute News
4576 FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was ¥87.00 and its highest was ¥181.00 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is ¥5.38B.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is May 07, 2026 which is in 60 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on Feb 13, 2026. The company reported -¥2.44 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.44.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 54,356,712 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -¥2.44 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in JP:4576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D.Western Therapeutics Institute (4576) is a biotechnology company focused on developing innovative therapeutic solutions for various medical conditions. Operating primarily in the healthcare sector, the company specializes in research and development of biologics and small-molecule drugs aimed at treating chronic diseases, particularly in oncology and autoimmune disorders. With a commitment to advancing science and improving patient outcomes, D.Western Therapeutics Institute leverages cutting-edge technology and extensive clinical research to create effective treatment options.